| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DLEU2 |
| Uniprot No | O43262 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-84aa |
| 氨基酸序列 | MRLRFNNDRMKTTIKETTILSSAILTFLTYLMKMSFERCTARNKMFVNSPFYPRVDNYCTSSWKKFYLKCYFSLNTIKKEKKMT |
| 分子量 | 36.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人DLEU2蛋白及相关研究的3篇文献示例(注：经检索，关于重组人DLEU2蛋白的直接研究较少，以下内容为模拟示例，实际文献需通过学术数据库验证)：
---
1. **文献名称**: *Long non-coding RNA DLEU2 promotes tumorigenesis via interacting with histone modifiers in lymphoma*
**作者**: Zhang L. et al.
**摘要**: 研究揭示了DLEU2作为促癌lncRNA在淋巴瘤中的作用，通过重组人DLEU2蛋白体外实验，发现其与组蛋白甲基转移酶EZH2的物理互作，调控下游靶基因沉默并促进肿瘤细胞增殖。
2. **文献名称**: *DLEU2-encoded protein suppresses apoptosis in chronic lymphocytic leukemia*
**作者**: Wang Y. et al.
**摘要**: 首次报道DLEU2基因编码的小分子蛋白(通过重组技术表达)可抑制B细胞凋亡，并激活PI3K/AKT通路，为慢性淋巴细胞白血病的治疗提供新靶点。
3. **文献名称**: *Recombinant DLEU2 protein enhances endothelial cell angiogenesis in vitro*
**作者**: Chen H. et al.
**摘要**: 构建重组人DLEU2蛋白并验证其促血管生成功能，通过细胞实验表明其通过结合VEGF受体增强信号传导，可能参与肿瘤微环境调控。
---
**备注**：实际研究中，**DLEU2主要作为长链非编码RNA(lncRNA)**被报道，其蛋白编码功能或重组蛋白研究较少。建议结合具体需求扩展关键词(如"DLEU2 interactome"或相关疾病模型)检索最新文献。
**Background of Recombinant Human DLEU2 Protein**
The deleted in lymphocytic leukemia 2 (DLEU2) gene, located on chromosome 13q14.3. encodes a long non-coding RNA (lncRNA) implicated in tumorigenesis and immune regulation. This locus is frequently deleted in chronic lymphocytic leukemia (CLL) and other cancers, suggesting a tumor-suppressive role. While DLEU2 is primarily transcribed as a non-coding RNA, recombinant human DLEU2 protein has been engineered to study potential protein-coding isoforms or small open reading frames (sORFs) within the transcript, which might contribute to its biological functions.
The DLEU2 lncRNA regulates apoptosis, cell cycle progression, and B-cell receptor signaling by interacting with miRNAs (e.g., miR-15a/16-1) or chromatin modifiers. Recombinant DLEU2 protein enables exploration of its direct molecular interactions, structural features, and mechanisms in disease contexts. Studies using this protein aim to clarify its role in cancer pathways, immune evasion, and epigenetic regulation. Additionally, it serves as a tool for drug screening or therapeutic targeting, particularly in hematologic malignancies. Further research is needed to validate its functional significance and therapeutic potential beyond its non-coding RNA identity.
×
